|
1
|
Shah AR, Lazar EL and Atlas AB: Tracheal
diverticula after tracheoesophageal fistula repair: Case series and
review of the literature. Pediatr Surg. 44:2107–2111. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Escudier B, Goupil MG, Massard C and
Fizazi K: Sequential therapy in renal cell carcinoma. Cancer. 115
(10 Suppl):S2321–S2326. 2009. View Article : Google Scholar
|
|
3
|
Fleshner NE, Herr HW, Stewart AK, Murphy
GP, Mettlin C and Menck HR: The national cancer data base report on
bladder carcinoma. The American college of surgeons commission on
cancer and the American Cancer Society. Cancer. 78:1505–1513. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim KH and Roberts CWM: Targeting EZH2 in
cancer. Nat Med. 22:128–134. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen M and Li CM: MRI diagnosis points and
clinical treatment options of prostate cancer. Chin J Magn Reson
Imaging. 2:82011.(In Chinese).
|
|
6
|
Ding HM and Li L: The application of
prostate specific antigen in the diagnosis of prostate cancer. Int
Med Health Guid News. 13:32007.(In Chinese).
|
|
7
|
Chen H, Rossier C and Antonarakis SE:
Cloning of a human homolog of the Drosophila enhancer of zeste gene
(EZH2) that maps to chromosome 21q22.2. Genomics. 38:30–37. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bachmann IM, Halvorsen OJ, Collett K,
Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP and
Akslen LA: EZH2 expression is associated with high proliferation
rate and aggressive tumor subgroups in cutaneous melanoma and
cancers of the endometrium, prostate, and breast. J Clin Oncol.
24:268–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kuzmichev A, Jenuwein T, Tempst P and
Reinberg D: Different EZH2-containing complexes target methylation
of histone H1 or nucleosomal histone H3. Mol Cell. 14:183–193.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tonini T, Bagella L, D'Andrilli G, Claudio
PP and Giordano A: Ezh2 reduces the ability of HDAC1-dependent
pRb2/p130 transcriptional repression of cyclin A. Oncogene.
23:4930–4937. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jang SH, Lee JE, Oh MH, Lee JH, Cho HD,
Kim KJ, Kim SY, Han SW, Kim HJ, Bae SB and Lee HJ: High EZH2
protein expression is associated with poor overall survival in
patients with luminal a breast cancer. J Breast Cancer. 19:53–60.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu C, Jin X, Yang J, Yang Y, He Y, Ding L,
Pan Y, Chen S, Jiang J and Huang H: Inhibition of EZH2 by chemo-
and radiotherapy agents and small molecule inhibitors induces cell
death in castration-resistant prostate cancer. Oncotarget.
7:3440–3452. 2015. View Article : Google Scholar
|
|
14
|
Kuroki H, Hayashi H, Okabe H, Hashimoto D,
Takamori H, Nakahara O, Nakagawa S, Fukushima Y, Chikamoto A, Beppu
T, et al: EZH2 is associated with malignant behavior in pancreatic
IPMN via p27Kip1 downregulation. PLoS One. 9:e1009042014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo L, Yang TF, Liang SC, Guo JX and Wang
Q: Role of EZH2 protein expression in gastric carcinogenesis among
Asians: A meta-analysis. Tumour Biol. 35:6649–6656. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lv YJ, Ren M, Wang B, Ge RQ and Zhang JD:
Expressions of CTGF and EZH2 in renal clear cell carcinoma and
their clinical significance. J Shandong Univ (Health Sci).
49:85–89. 2011.
|
|
17
|
Xu ST, Yan CY, Huang YH and Ding X:
Research about expression of EZH2 and P53 in human renal cell
carcinoma. Chin J Mod Med. 20:736–737. 2010.(In Chinese).
|
|
18
|
Liu F, Xiao RH, Hong ZD, Lu XB, Shi ZM, Xi
XQ and Pan ZY: Expression of EZH2 and P57 in renal cell carcinoma
and its clinical significance. Pract Clin Med. 14:23–25. 2013.(In
Chinese).
|
|
19
|
Li HB, Wang H and Wu GJ: Expression of
EZH2 and PTEN in renal clear cell carcinoma and their correlation.
J Shanxi Med Univ. 40:199–201. 2009.(In Chinese).
|
|
20
|
Dan JF, Zhuang QY, Liu F and Peng EJ:
Expression and correlation of EZH2 and RUNX3 in Renal clear cell
carcinoma. J Clin Urol. 27:567–571. 2012.(In Chinese).
|
|
21
|
Wang G, Qin W, Zheng J, Wei M, Zhou X,
Wang H and Wen HW: Expressions of EZH2 and RUNX3 in renal cell
carcinoma and their clinical significance. Xi Bao Yu Fen Zi Mian Yi
Xue Za Zhi. 29:82–84. 2013.(In Chinese). PubMed/NCBI
|
|
22
|
Wagener N, Macher-Goeppinger S, Pritsch M,
Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp
A, Hoppe-Seyler F and Hohenfellner M: Enhancer of zeste homolog 2
(EZH2) expression is an independent prognostic factor in renal cell
carcinoma. BMC Cancer. 10:5242010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee HW and Choe M: Expression of EZH2 in
renal cell carcinoma as a novel prognostic marker. Pathol Int.
62:735–741. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eichenauer T, Simmendinger L, Fraune C,
Mandelkow T, Blessin NC, Kluth M, Hube-Magg C, Möller K, Clauditz
T, Weidemann S, et al: High level of EZH2 expression is linked to
high density of CD8-positive T-lymphocytes and an aggressive
phenotype in renal cell carcinoma. World J Urol. 9:481–490. 2021.
View Article : Google Scholar
|
|
25
|
Wang Y, Chen Y, Geng H, Qi C, Liu Y and
Yue D: Overexpression of YB1 and EZH2 are associated with cancer
metastasis and poor prognosis in renal cell carcinomas. Tumour
Biol. 36:7159–7166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liao B and Yang ZB: Expression and
clinical significance of EZH2, FHIT and VEGF in bladder urothelial
carcinoma. Chin J Oncol Prev Treat. 5:142–144. 2013.(In
Chinese).
|
|
27
|
Xu ST, Shao XF, Jiang T and Liu F:
Expression and significance of EZH2 and Ki67 in human bladder
transitional cell carcinoma. Mod Med J Chin. 12:72–74. 2010.(In
Chinese).
|
|
28
|
Liu F, Peng EJ, Li YY, Qi Y, Du LH and
Zhuang QY: Correlation of EZH2 and PTEN gene expression with
disease free survival of bladder transitional cell carcinoma
patients. Chin J Clin Oncol. 37:1220–1223. 2010.(In Chinese).
|
|
29
|
Cai YJ, Zhang XJ, Ke M and Hong T:
Expression of EZH2 gene in bladder urothelial carcinoma and its
relationship with clinicopathological parameters. Mod Chin Doctor.
57:1–3. 2019.(In Chinese).
|
|
30
|
Li HB, Wang H, Wu GJ and Zhou ZM:
Expression of EZH2gene in urothelial carcinoma of bladder and its
clinical value. J Shanxi Med Univ. 39:530–533. 2008.(In
Chinese).
|
|
31
|
Zhang YB, Niu HT and Chang JW: Expression
and clinical significance of EZH2 in transitional cell carcinoma of
bladder. Clin Med China. 24:193–195. 2008.(In Chinese).
|
|
32
|
Arisan S, Buyuktuncer ED, Palavan-Unsal N,
Caşkurlu T, Cakir OO and Ergenekon E: Increased expression of EZH2,
a polycomb group protein, in bladder carcinoma. Urol Int.
75:252–257. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li WD, Wu Q, Ma CM and Wang HQ: Expression
of EZH2 in prostate cancer and its clinicopathologic significance.
Acta Unive Med Anhui. 45:562–564. 2010.(In Chinese).
|
|
34
|
Zheng J, Li XG and Jin TX: Expression and
clinical significance of EZH2 and P27 in prostate carcinoma and
benign prostatic hyperplasia. J Med Sci Yanbian Univ. 35:272–276.
2012.(In Chinese).
|
|
35
|
Song L, Cui XJ, Su DJ and Tan GL:
Expression and correction of EZH2 and PTEN in prostate cancer. J
Fourth Mil Med Univ. 27:994–996. 2006.(In Chinese).
|
|
36
|
Sun YS, Li FJ, Gao Y, Jia HB, Wang QY, Qin
WJ, Wen HW and Wang H: The expression of EZH2 in the prostate
cancer tissues and its clinical significance. J Mod Oncol.
22:1351–1353. 2014.
|
|
37
|
Li J, Fan QH, Fan XS, Zhou W, Qiu Y and
Qiu L: EZH2 expression in human prostate cancer and its
clinicopathologic significance. Zhonghua Nan Ke Xue. 16:123–128.
2010.(In Chinese). PubMed/NCBI
|
|
38
|
Zhang SG, Qiu Y, Qiu L, Wu Y and Ding Y:
Expressions and significance of P504S‚EZH2and pim-1in prostate
cancer. J Contemp Urol Reprod Oncol. 2:354–356. 2010.
|
|
39
|
Li J, Qiu Y and Qiu L: Significance of
detection of mixed type antibody EZH2/34βE12/p63 in needle biopsy
specimen of prostatic lesions. Pract Geriatr. 31:458–460. 2017.
|
|
40
|
Zheng C, Wang Z and Cao YG: Drosophila
Zeste gene enhancer 2, phosphatase and tensin in prostate
adenocarcinoma tissue homologous protein expression and its effect
on Ki67 proliferation index. Chin J Gerontol. 6:2946–2947. 2016.(In
Chinese).
|
|
41
|
Ruan Y, Xu H, Ji X and Zhao J: BLM
interaction with EZH2 regulates MDM2 expression and is a poor
prognostic biomarker for prostate cancer. Am J Cancer Res.
11:1347–1368. 2021.PubMed/NCBI
|
|
42
|
Melling N, Thomsen E, Tsourlakis MC, Kluth
M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C,
et al: Overexpression of enhancer of zeste homolog 2 (EZH2)
characterizes an aggressive subset of prostate cancers and predicts
patient prognosis independently from pre- and postoperatively
assessed clinicopathological parameters. Carcinogenesis.
36:1333–1340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li X, Wen ZL and Tu XL: Research progress
on EZH2. J Clin Ration Drug Use. 10:32017.(In Chinese).
|
|
44
|
Simon JA and Lange CA: Roles of the EZH2
histone methyltransferase in cancer epigenetics. Mutat Res.
647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Viré E, Brenner C, Deplus R, Blanchon L,
Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden
JM, et al: The polycomb group protein EZH2 directly controls DNA
methylation. Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhou L, Mudianto T, Ma X, Riley R and
Uppaluri R: Targeting EZH2 enhances antigen presentation, antitumor
immunity, and circumvents Anti-PD-1 resistance in head and neck
cancer. Clin Cancer Res. 26:290–300. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yao F, Liu C, Fang Y, et al: The
expression and clinical significance of EZH2 in breast cancer. Chin
J Microecol. 25:42013.(In Chinese).
|
|
48
|
Bracken AP, Pasini D, Capra M, Prosperini
E, Colli E and Helin K: EZH2 is downstream of the pRB-E2F pathway,
essential for proliferation and amplified in cancer. EMBO J.
22:5323–5335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao YS, Ji MD, Dong LC, Guo X, Song BY
and Chen Y: Epigenetic regulation mechanism of EZH2 gene in
hepatocellular carcinoma. Basic Clin Med. 42:864–870. 2022.
|
|
50
|
Peng Y, Chen HB, Su ZJ, Chen L, Zhang JK
and Xu LY: Expression of EZH2 protein in esophageal cancer tissue.
Acta Anat Sin. 37:62006.(In Chinese).
|
|
51
|
Hou FH, Su YH, Bu YJ, Wang X and Hou ZB:
Prognostic value of EZH2,Ki-67 and CD34 expression in patients with
surgically treated colorectal cancer. J Sun Yat-Sen Univ (Med Sci).
866–872. 2017.
|
|
52
|
Wang A, Dai H, Gong Y, Zhang C, Shu J, Luo
Y, Jiang Y, Liu W and Bie P: ANLN-induced EZH2 upregulation
promotes pancreatic cancer progression by mediating
miR-218-5p/LASP1 signaling axis. J Exp Clin Cancer Res. 38:3472019.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Huang WN, Gu LN, Liu F and Sang M: Effect
of EZH2 gene on proliferation of human esophageal cancer cells.
Chin J Cancer Biother. 24:960–965. 2017.(In Chinese).
|
|
54
|
Gan L, Xu M, Hua R, Tan C, Zhang J, Gong
Y, Wu Z, Weng W, Sheng W and Guo W: The polycomb group protein EZH2
induces epithelial-mesenchymal transition and pluripotent phenotype
of gastric cancer cells by binding to PTEN promoter. J Hematol
Oncol. 11:92018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen S, Pu J, Bai J, Yin Y, Wu K, Wang J,
Shuai X, Gao J, Tao K, Wang G and Li H: EZH2 promotes
hepatocellular carcinoma progression through modulating
miR-22/galectin-9 axis. J Exp Clin Cancer Res. 37:32018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhou X, Gao W, Hua H and Ji Z:
LncRNA-BLACAT1 facilitates proliferation, migration and aerobic
glycolysis of pancreatic cancer cells by repressing CDKN1C via
EZH2-induced H3K27me3. Front Oncol. 10:5398052020. View Article : Google Scholar : PubMed/NCBI
|
